DexCom, Inc. (DXCM) NASDAQ

73.56

+1.22(+1.69%)

Updated at May 29 01:12PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Jacob Steven Leach	President, CEO & Director	2.05M	1978
Girish Naganathan	Executive Vice President & Chief Technology Officer	423,920	1977
Donald Abbey	Executive Vice President of Global Business Services, Regulatory, Medical & Clinical Affairs	766,800	1967
Sadie Stern	Executive Vice President & Chief Human Resources Officer	1.01M	1975
Jon Coleman	Executive Vice President & Chief Commercial Officer	1.01M	1964
Michael Brown	Executive Vice President & Chief Legal Officer	1.1M	1970
Jereme Sylvain	Executive Vice President, Chief Financial Officer & Chief Accounting Officer	1.14M	1980
Kevin Ronald Sayer	Executive Chairman of the Board	2.43M	1958
Sean Christensen	Vice President of Finance and Investor Relations	0	N/A
Matthew Dolan	Executive Vice President of Strategy & Corporate Development	0	1981
Keri Leone	Senior Director of Global Medical Science & Education	0	N/A

Name

Title

Pay

Year Born

Jacob Steven Leach

President, CEO & Director

2.05M

1978

Girish Naganathan

Executive Vice President & Chief Technology Officer

423,920

1977

Donald Abbey

Executive Vice President of Global Business Services, Regulatory, Medical & Clinical Affairs

766,800

1967

Sadie Stern

Executive Vice President & Chief Human Resources Officer

1.01M

1975

Jon Coleman

Executive Vice President & Chief Commercial Officer

1.01M

1964

Michael Brown

Executive Vice President & Chief Legal Officer

1.1M

1970

Jereme Sylvain

Executive Vice President, Chief Financial Officer & Chief Accounting Officer

1.14M

1980

Kevin Ronald Sayer

Executive Chairman of the Board

2.43M

1958

Sean Christensen

Vice President of Finance and Investor Relations

N/A

Matthew Dolan

Executive Vice President of Strategy & Corporate Development

1981

Keri Leone

Senior Director of Global Medical Science & Education

N/A

Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.